Asset Details
Do you wish to reserve the book?
A Multicenter Randomized Trial of Atorvastatin Therapy in Intensive Care Patients with Severe Sepsis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A Multicenter Randomized Trial of Atorvastatin Therapy in Intensive Care Patients with Severe Sepsis
Do you wish to request the book?
A Multicenter Randomized Trial of Atorvastatin Therapy in Intensive Care Patients with Severe Sepsis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A Multicenter Randomized Trial of Atorvastatin Therapy in Intensive Care Patients with Severe Sepsis
2013
Overview
Abstract
Rationale
Observational studies link statin therapy with improved outcomes in patients with severe sepsis.
Objectives
To test whether atorvastatin therapy affects biologic and clinical outcomes in critically ill patients with severe sepsis.
Methods
Phase II, multicenter, prospective, randomized, double-blind, placebo-controlled trial stratified by site and prior statin use. A cohort of 250 critically ill patients (123 statins, 127 placebo) with severe sepsis were administrated either atorvastatin (20 mg daily) or matched placebo.
Measurements and Main Results
There was no difference in IL-6 concentrations (primary end point) between the atorvastatin and placebo groups (P = 0.76) and no interaction between treatment group and time to suggest that the groups behaved differently over time (P = 0.26). Baseline plasma IL-6 was lower among previous statin users (129 [87–191] vs. 244 [187–317] pg/ml; P = 0.01). There was no difference in length of stay, change in Sequential Organ Failure Assessment scores or mortality at intensive care unit discharge, hospital discharge, 28- or 90-day (15% vs. 19%), or adverse effects between the two groups. Cholesterol was lower in patients treated with atorvastatin (2.4 [0.07] vs. 2.6 [0.06] mmol/L; P = 0.006). In the predefined group of 77 prior statin users, those randomized to placebo had a greater 28-day mortality (28% vs. 5%; P = 0.01) compared with those who received atorvastatin. The difference was not statistically significant at 90 days (28% vs. 11%; P = 0.06).
Conclusions
Atorvastatin therapy in severe sepsis did not affect IL-6 levels. Prior statin use was associated with a lower baseline IL-6 concentration and continuation of atorvastatin in this cohort was associated with improved survival.
Clinical trial registered with the Australian New Zealand Clinical Trials Registry (ACTRN 12607000028404).
Publisher
Oxford University Press,American Thoracic Society
Subject
/ Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
/ Biological and medical sciences
/ C-Reactive Protein - analysis
/ Consent
/ Female
/ Heptanoic Acids - therapeutic use
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
/ Kinases
/ Male
/ Patients
/ Pharmacy
/ Sepsis
/ Statins
